Zhixiang Jintai: Signed a cooperation agreement and received an initial payment of 260 million yuan and a milestone payment of up to 250 million yuan.

Zhixiang Jintai announced recently that the company has signed exclusive cooperation agreements with the subsidiary company of Convergent Pharmaceuticals, Tibet Convergent Pharmaceuticals Development Co., Ltd., and RXILIENT MEDICAL PTE. LTD. for the exclusive commercialization rights of Veklury monoclonal antibody injection and Remdesivir monoclonal antibody injection, respectively. According to the agreements, the company will receive upfront payments, milestone payments, and commercialization services. Tibet Convergent will obtain the exclusive commercialization rights of the two products in mainland China, while RXILIENT will receive the exclusive licensing rights of the two products in the Asia-Pacific region, as well as the Middle East and North Africa regions.